Cargando…

Immunotherapies for Malignant Glioma

Glioblastoma Multiforme (GBM) is a highly malignant primary brain cancer with a dreadful overall survival and for which treatment options are limited. Recent breakthroughs in novel immune-related treatment strategies for cancer have spurred interests in usurping the power of the patient's immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boussiotis, Vassiliki A., Charest, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828703/ https://www.ncbi.nlm.nih.gov/pubmed/29242608 http://dx.doi.org/10.1038/s41388-017-0024-z

Ejemplares similares

T Cell Metabolism in Cancer Immunotherapy
por: Aksoylar, Halil-Ibrahim, et al.
Publicado: (2020)

Immunotherapy for malignant glioma
por: Suryadevara, Carter M., et al.
Publicado: (2015)

Commentary on: Combination of Metabolic Intervention and T Cell Therapy Enhances Solid Tumor Immunotherapy
por: Christofides, Anthos, et al.
Publicado: (2021)

Glioma Stem Cells and Immunotherapy for the Treatment of Malignant Gliomas
por: Toda, Masahiro
Publicado: (2013)

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
por: Ibis, Betul, et al.
Publicado: (2023)

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy
por: Le Bourgeois, Thibault, et al.
Publicado: (2018)

Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells
por: Bardhan, Kankana, et al.
Publicado: (2019)

Publisher Correction: Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells
por: Bardhan, Kankana, et al.
Publicado: (2020)

Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
por: Yeo, Alan T., et al.
Publicado: (2023)

Effects of PD-1 Signaling on Immunometabolic Reprogramming
por: Boussiotis, Vassiliki A., et al.
Publicado: (2022)

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
por: Karantanos, Theodoros, et al.
Publicado: (2017)

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
por: Bardhan, Kankana, et al.
Publicado: (2016)

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy
por: Chuntova, Pavlina, et al.
Publicado: (2019)

Runx1 and Runx3 Are Involved in the Generation and Function of Highly Suppressive IL-17-Producing T Regulatory Cells
por: Li, Lequn, et al.
Publicado: (2012)

A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy
por: Chung, Dong-Sup, et al.
Publicado: (2014)

Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2
por: Christofides, Anthos, et al.
Publicado: (2016)

Revisiting the PD-1 pathway
por: Patsoukis, Nikolaos, et al.
Publicado: (2020)

CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
por: Filley, Anna C., et al.
Publicado: (2018)

DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker
por: Zhang, Jingwen, et al.
Publicado: (2021)

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy
por: Teng, Chubei, et al.
Publicado: (2022)

Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study
por: Jiang, Haihui, et al.
Publicado: (2021)

Characterization of plasma-derived protoporphyrin-IX-positive extracellular vesicles following 5-ALA use in patients with malignant glioma
por: Jones, Pamela S., et al.
Publicado: (2019)

Glioma Immunotherapy: Advances and Challenges for Spinal Cord Gliomas
por: Grady, Clare, et al.
Publicado: (2022)

Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant
por: Wei, Jingjing, et al.
Publicado: (2022)

Regulation of T Cell Differentiation and Function by EZH2
por: Karantanos, Theodoros, et al.
Publicado: (2016)

Corrigendum: Regulation of T Cell Differentiation and Function by EZH2
por: Karantanos, Theodoros, et al.
Publicado: (2016)

Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression
por: Yeo, Alan T., et al.
Publicado: (2022)

Natural Products for the Immunotherapy of Glioma
por: Huang, Qi, et al.
Publicado: (2023)

Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease
por: Tijaro-Ovalle, Natalia M., et al.
Publicado: (2019)

Understanding the Mechanisms of Diet and Outcomes in Colon, Prostate, and Breast Cancer; Malignant Gliomas; and Cancer Patients on Immunotherapy
por: Mann, Shivtaj, et al.
Publicado: (2020)

Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
por: Yoshikawa, Sayuri, et al.
Publicado: (2022)

Immunotherapy in genitourinary malignancies
por: Mehta, Kathan, et al.
Publicado: (2017)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Impact of General Factors on Glioma Immunotherapy
por: Huang, Qilin, et al.
Publicado: (2022)

Clinical and Translational Advances in Glioma Immunotherapy
por: Bunse, Lukas, et al.
Publicado: (2022)

Translational Models in Glioma Immunotherapy Research
por: Ren, Alexander L., et al.
Publicado: (2023)

Immunotherapy of Genitourinary Malignancies
por: Inamoto, Teruo, et al.
Publicado: (2012)

Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses
por: Patsoukis, Nikolaos, et al.
Publicado: (2017)

Clinical significance of T cell metabolic reprogramming in cancer
por: Herbel, Christoph, et al.
Publicado: (2016)

Gene therapy for malignant glioma
por: Okura, Hidehiro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4vk4rqtp251hv4tn0qi56mubfd